Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

Completed · Phase 1

Conditions studied: Pterygium

In brief

Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.

Key facts

Study ID

NCT01169909

Run by

University of New Mexico

People needed

10

Starts

2010-08-01

Expected to finish

2014-07-01

Last updated by the study team

2016-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with actively growing pterygia, either surgical recurrences, or non-surgical primary lesions.

You may not qualify if…

• Pregnancy
• History of CVA
• Monocular patients
• Minors

Where it is running

• University of New Mexico Health Science Center — Albuquerque, New Mexico, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.